Even major CaMBPs that have been proven to be central to critical events in AD (e.g., CaMKIIα, PP2B) are apparently not targets of ongoing drug trials even though existing FDA-approved pharmaceuticals that target them already exist. This evidence concerns the gene CAMK2A and Alzheimer disease.